Beta-defensin 2, Human, clone HB12G9
Monoclonal antibody HB12G9 recognized human beta defensin-2 (HBD2). hBD-2 is a cysteine-rich cationic 41 amino acid antimicrobial peptide of 4-5 kDa.
Read moreMonoclonal antibody HB12G9 recognized human beta defensin-2 (HBD2). hBD-2 is a cysteine-rich cationic 41 amino acid antimicrobial peptide of 4-5 kDa. Human BD-2 is produced by epithelial cells upon stimulus by lipopolysaccharides and proinflammatory cytokines TNFα and IL1β. Contact of keratinocytes with gram-negative bacteria results in rapid induction of hBD-2 protein. hBD-2 has been described as a dynamic component of the local epithelial defense system of the skin, intestinal and respiratory tract, where it functions by protecting surfaces from infection. Its local expression has been associated with skin lesions like psoriasis as well as infected lung epithelia of patients with cystic fibrosis. Furthermore, in inflammatory bowel disease (IBD), expression of hBD-2 is increased in patients with IBD compared to healthy persons. The NF-kB pathway has been recognized as a key component in the induction of hBD-2 expression, however, other studies have observed induction mediated by the mitogen-activated protein kinase (MAPK) pathways. Thus, increased expression of hBD-2 in epithelial cells is associated with the proinflammatory response. This is supported by the finding that the anti-inflammatory cytokines IL-10 and IL-13 downregulate the synthesis of hBD-2 in atopic dermatitis.
W: the monoclonal antibody is useful for Western blotting under non-reduced conditions.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA